Cumberland Pharmaceuticals (CPIX) Capital Expenditures Growth (1y) (2011 - 2026)
Analysis
Cumberland Pharmaceuticals (CPIX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 26.65% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 19.70% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 16.88% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 3.02% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -13.75% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | -34.92% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 73.63% |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | 44.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.54% |
| Dec 31, 2025 | -100.04% |
| Sep 30, 2025 | 54.68% |
| Jun 30, 2025 | 268.99% |
| Mar 31, 2025 | 14.44% |
| Dec 31, 2024 | -95.31% |
| Sep 30, 2024 | -71.06% |
| Jun 30, 2024 | -90.06% |
| Mar 31, 2024 | -61.20% |
| Dec 31, 2023 | 131.70% |
| Sep 30, 2023 | -41.88% |
| Jun 30, 2023 | -47.40% |
| Mar 31, 2023 | 297.47% |
| Dec 31, 2022 | -1,797.00% |
| Sep 30, 2022 | 52.51% |
| Jun 30, 2022 | 810.60% |
| Mar 31, 2022 | 38.69% |
| Dec 31, 2021 | -80.17% |
| Sep 30, 2021 | 35.32% |
| Jun 30, 2021 | -46.47% |